OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Schwartz on Results From the GIST Cohort in the Alliance A091401 Trial

August 6th 2020

Gary K. Schwartz, MD, discusses the results from the gastrointestinal stromal tumor cohort of the phase 2 Alliance A091401 trial.

Dr. Czerniecki on the Benefit of Tucatinib in HER2+ Breast Cancer and Brain Metastases

August 6th 2020

Brian Czerniecki, MD, PhD, discusses the benefit of tucatinib in patients with HER2-positive breast cancer and brain metastases.

Dr. Jonasch on Next Steps With MK-6482 in Von Hippel-Lindau Disease–Associated RCC

August 6th 2020

Eric Jonasch, MD, discusses the next steps with the potent, selective, small molecule hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Dr. Mascarenhas on Approved and Emerging Treatment Options in Myelofibrosis

August 6th 2020

John O. Mascarenhas, MD, discusses approved and emerging treatment options in myelofibrosis.

Dr. Lonial on the FDA Approval of Belantamab Mafodotin-blmf in Multiple Myeloma

August 6th 2020

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Dr. Roland on the Safety of Neoadjuvant Checkpoint Blockade in Sarcoma

August 5th 2020

Christina L. Roland, MD, MS, FACS, discusses the safety profile of neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Dr. Blank on Predictive Biomarkers in Macroscopic Stage III Melanoma

August 5th 2020

Christian U. Blank, MD, PhD, discusses the future of baseline biomarkers in macroscopic stage 3 melanoma.

Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Dr. Raje on Remaining Questions in Multiple Myeloma

August 5th 2020

Noopur S. Raje, MD, discusses remaining questions in multiple myeloma.

Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

August 5th 2020

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Dr. Mesa on Mitigating Racial Disparities in MPN Clinical Trials

August 5th 2020

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Dr. Maddocks on Treatment Considerations in Follicular Lymphoma

August 5th 2020

Kami J. Maddocks, MD, discusses treatment considerations for treatment selection in follicular lymphoma.

Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

August 5th 2020

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Dr. Balzarotti on Questions With Consolidation and Maintenance Therapy in R/R DLBCL

August 5th 2020

Monica Balzarotti, MD, discusses remaining questions regarding consolidation and maintenance therapy in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Palmer on the Treatment Landscape of aGVHD

August 4th 2020

Jeanne M. Palmer, MD, discusses the current treatment landscape of acute graft-versus-host disease.

Dr. Westin on Challenges With Precision Medicine in Endometrial Cancer

August 4th 2020

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer.

Dr. Shore on Challenges with ADT in Recurrent Prostate Cancer

August 4th 2020

Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.

Dr. Al-Sawaf on New Safety Signals With Venetoclax/Obinutuzumab in the CLL14 Trial

August 4th 2020

Othman Al-Sawaf, MD, discusses new safety signals with venetoclax plus obinutuzumab in the phase 3 CLL14 trial.

Dr. Shum on Patient Consultation of Osimertinib in NSCLC

August 4th 2020

Elaine Shum, MD, discusses consulting patients with non-small cell lung cancer on the use of osimertinib.

Dr. Kumar on Treatment Discontinuation in the ENDURANCE Myeloma Trial

August 4th 2020

Shaji K. Kumar, MD, discusses treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.